Boston Scientific (MEX:BSX) LT-Debt-to-Total-Asset: 0.25 (As of Mar. 2026)


MEX:BSX Boston Scientific Corp MEX:BSX
85 GF Score
Price MXN784.12
GF Value MXN1,849.32
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific LT-Debt-to-Total-Asset?

Boston Scientific MEX:BSX 85 LT-Debt-to-Total-Asset is 0.25 as of Mar. 2026. GuruFocus rates MEX:BSX with a GF Score™ of 85/100 and a GF Value™ of MXN1,849.32 (Significantly Undervalued). The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Boston Scientific's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.25.

Boston Scientific's long-term debt to total assets ratio declined from Mar. 2025 (0.27) to Mar. 2026 (0.25). It may suggest that Boston Scientific is progressively becoming less dependent on debt to grow their business.

Boston Scientific  (MEX:BSX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Boston Scientific LT-Debt-to-Total-Asset Related Terms

Boston Scientific LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Boston Scientific's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific LT-Debt-to-Total-Asset Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.29 0.26 0.23 0.26

Boston Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.28 0.27 0.26 0.25
MEX:BSX
85GF Score
Boston Scientific Corp MEX:BSX
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific LT-Debt-to-Total-Asset Calculation

Boston Scientific's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=200529.481/786362.937
=0.26

Boston Scientific's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=198143.308/799768.278
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.25 mean?
Boston Scientific (MEX:BSX) has a LT-Debt-to-Total-Asset of 0.25 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Boston Scientific and its competitors.
Is Boston Scientific's LT-Debt-to-Total-Asset too high?
Boston Scientific's current LT-Debt-to-Total-Asset is 0.25. Overall, Boston Scientific has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's LT-Debt-to-Total-Asset compare to EW and GEHC?
Boston Scientific's LT-Debt-to-Total-Asset of 0.25 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Boston Scientific and its competitors. Boston Scientific's current LT-Debt-to-Total-Asset is 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (MEX:BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,849.32, compared to a current price of MXN784.12 — trading 57.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.25. Boston Scientific's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Boston Scientific (MEX:BSX), the current LT-Debt-to-Total-Asset is 0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (MEX:BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of MXN784.12 is trading 57.6% below its estimated GF Value™ of MXN1,849.32. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for MEX:BSX:

  • LT-Debt-to-Total-Asset: 0.25
  • GF Value™: MXN1,849.32 vs. price of MXN784.12 (57.6% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the MEX:BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
85GF Score

Get the complete analysis for MEX:BSX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN784.12
Price
MXN1,849.32
GF Value